December 2016

New Product - Eloctate

Eloctate (efmoroctocog alfa (rhu)) is a long acting, fully recombinant fusion protein consisting of a human coagulation factor VIII (FVIII) covalently linked to the Fc domain of human IgG1. The factor VIII/von Willebrand factor (FVIII/VWF) complex consists of 2 molecules (FVIII and von Willebrand factor) with different physiological functions. Upon activation of the clotting cascade, FVIII is converted to activated FVIII (FVIIIa) and released from VWF. Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X on phospholipid surfaces, and which ultimately converts prothrombin to thrombin and leads to the formation of a fibrin clot. Eloctate, a long acting antihaemophilic factor (recombinant) is indicated in adults and children with haemophilia A (congenital factor VIII deficiency) for control and prevention of bleeding episodes; routine prophylaxis to prevent or reduce the frequency of bleeding episodes; and in perioperative management (surgical prophylaxis). Eloctate does not contain von Willebrand factor, and therefore is not indicated in patients with von Willebrand’s disease. Eloctate is available as a powder for infusion in 7 different vial sizes namely 250 IU, 500 IU, 750 IU, 1000 IU, 1500 IU, 2000 IU and 3000 IU in packs of 1’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629